HC restrains firm from infringing copyright of Mankind Pharma

Image
Press Trust of India New Delhi
Last Updated : Jul 19 2019 | 7:21 PM IST

The Delhi High Court has restrained a pharmaceutical firm from infringing the copyright of Mankind Pharma in the contents of its website.

Justice Prathiba M Singh said considering the evidence and the content of the website of Lee Pharmaceuticals of Lee House being identical, a permanent injunction is liable to be granted in favour of plaintiff Mankind Pharma Ltd and against the defendant.

"...a permanent injunction is liable to be granted in favour of the plaintiff against the defendant restraining the defendant from in any manner infringing the copyright of the plaintiff in the contents of its website www.mankindpharma.com. Further, the defendant is also restrained from passing off its business as being affiliated to that of the plaintiff. The suit is accordingly, decreed..," the court said.

Mankind Pharma said it was selling various medicinal preparations and over the counter drugs (OTCs) and has various domain names registered in its name with the mark 'MANKIND', however, its main website is www.mankindpharma.com.

It said that Lee Pharmaceuticals was incorporated in 2013 and the plaintiff came to know in February 2014, that the defendant has a website www.leepharmaceuticals.in.

A perusal of the website revealed that the entire website, including the photographs, images, etc. of the plaintiff has been copied by the defendant, it said.

As no one appeared for the defendant firm even after being served with the notice, the court proceeded ex-parte.

After going through the screenshots of the websites of both the companies, the court said use of such identical content is not only infringement of the plaintiff's copyright but could also lead to misrepresentation that the defendant is either affiliated to, or is a group company of the plaintiff.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 19 2019 | 7:21 PM IST

Next Story